Allopurinol vs. Alternatives: A Comprehensive Comparison

By Lindsey Smith On 17 Oct, 2025 Comments (5)

Gout Medication Selection Tool

This tool helps you determine which gout medication might be most appropriate based on your kidney function, cardiovascular risk, and current medications.

Your Health Profile

eGFR (kidney function)

Cardiovascular risk

Current medications

Aspirin

Thiazide diuretics

Cyclosporine

None

Recommendations

Quick Takeaways

Allopurinol is a xanthine oxidase inhibitor that lowers uric acid production, making it a first‑line drug for chronic gout.
Febuxostat offers similar efficacy with a lower dose‑adjustment burden in mild‑to‑moderate renal impairment.
Probenecid works by increasing uric acid excretion; it’s useful when uric acid production is already low.
Lesinurad and topiroxostat are newer options that target uric acid transporters or enzyme activity, respectively, but have limited long‑term safety data.
Choosing the right drug depends on kidney function, cardiovascular risk, drug‑interaction profile, and cost considerations.

When treating gout, Allopurinol is a xanthine oxidase inhibitor that reduces uric acid synthesis. It has been the backbone of chronic gout management for decades, yet a growing list of alternatives now competes for the same therapeutic niche. This guide walks you through the science, the safety profiles, and the practical trade‑offs so you can decide which option fits your situation best.

What Is Allopurinol and How Does It Work?

Allopurinol blocks the enzyme xanthine oxidase, which converts hypoxanthine and xanthine into uric acid. By curbing this final step, plasma urate levels fall, preventing crystal formation in joints and soft tissues. The typical starting dose is 100mg once daily, titrated up to 300mg (or 400mg in some cases) based on serum urate targets (<6mg/dL). For patients with severe renal impairment, the dose is reduced to 50‑100mg daily.

Common side effects include rash, elevated liver enzymes, and, rarely, allopurinol hypersensitivity syndrome-a severe reaction that demands immediate cessation of the drug. Monitoring liver function and renal labs every 2‑4weeks during dose escalation is standard practice.

Key Alternatives to Allopurinol

Below are the most frequently considered alternatives, each with a distinct mechanism.

Febuxostat is a non‑purine selective xanthine oxidase inhibitor. It achieves comparable urate lowering at doses of 40‑80mg daily and requires minimal dose adjustment for mild‑to‑moderate renal dysfunction.

Probenecid is a uricosuric agent that blocks renal tubular reabsorption of uric acid, increasing its excretion. It is best used in patients with good kidney function (eGFR>50mL/min) and in those who have not responded to uric‑acid‑production inhibitors.

Lesinurad is a selective uric acid transporter (URAT1) inhibitor used in combination with a xanthine oxidase inhibitor. The usual dose is 200mg daily, added to an existing Allopurinol or Febuxostat regimen.

Topiroxostat is another xanthine oxidase inhibitor approved in Japan, showing similar potency to Allopurinol. It is still gaining regulatory approval worldwide, so data are limited.

Anime-style illustration of uric acid crystals blocked by Allopurinol and other drugs.

Side‑Effect Profiles at a Glance

Comparison of Major Gout Medications
Drug	Mechanism	Typical Dose	Renal Adjustment	Key Side Effects	UK Cost (approx.)
Allopurinol	Xanthine oxidase inhibitor	100‑300mg/d	Yes, reduce if eGFR<30	Rash, hepatic ↑, hypersensitivity	£2‑£5 per month
Febuxostat	Selective xanthine oxidase inhibitor	40‑80mg/d	Minimal	Cardiovascular events, liver ↑	£30‑£45 per month
Probenecid	Uricosuric (URAT1 blocker)	250‑500mg 2‑3×/d	Not recommended	Kidney stones, GI upset	£5‑£8 per month
Lesinurad	URAT1 inhibitor (add‑on)	200mg/d (with XO‑inhibitor)	Reduce to 200mg if eGFR30‑50	Renal toxicity, rash	£25‑£35 per month
Topiroxostat	Xanthine oxidase inhibitor	30‑60mg/d	Limited data	Elevated liver enzymes	£20‑£30 per month (est.)

When to Choose Allopurinol vs. an Alternative

Allopurinol remains the first‑line choice for most patients because of its long‑track record, low price, and broad safety data. However, specific clinical scenarios tip the balance toward an alternative:

Renal impairment: If eGFR is 30‑60mL/min, febuxostat often achieves target urate without aggressive dose reduction.
Cardiovascular risk: Some studies link febuxostat to higher cardiovascular events, making allopurinol or probenecid safer for high‑risk patients.
Allopurinol hypersensitivity: In patients with a history of rash or severe reaction, switching to febuxostat or a uricosuric agent is prudent.
Uricosuric advantage: When underexcretion of uric acid is the primary problem (identified via 24‑hour urine collection), probenecid or lesinurad can be more effective.
Cost constraints: Allopurinol is the cheapest; patients on limited budgets often stay on it unless side‑effects force a switch.

Step‑by‑Step Checklist for Switching from Allopurinol

Confirm target serum urate (<6mg/dL) and document current dose.
Assess renal function (eGFR) and liver enzymes.
Identify the reason for switching (e.g., hypersensitivity, inadequate control, renal dose‑limit).
Select the new agent based on the decision matrix above.
Overlap therapy: start the new drug at a low dose while tapering Allopurinol over 1‑2weeks to avoid flare‑ups.
Schedule follow‑up labs at 2‑4weeks to verify urate reduction and monitor for adverse events.
Educate the patient on signs of severe rash, hepatic symptoms, or kidney stones, and provide an emergency contact.

Patient reviewing drug icons and a checklist to decide gout treatment.

Practical Tips for Clinicians and Patients

Always start prophylactic colchicine or NSAIDs when initiating or changing urate‑lowering therapy to prevent acute gout attacks.
Use the 24‑hour urine uric acid test to differentiate over‑production vs. under‑excretion patterns.
Check for drug‑drug interactions: probenecid can increase plasma levels of penicillins and ceftriaxone; febuxostat may interact with azathioprine.
Consider genetic testing for HLA‑B*58:01 in patients of Asian descent before starting Allopurinol, as they have a higher risk of hypersensitivity.
For patients on dialysis, low‑dose Allopurinol (50mg) is often sufficient; alternatives generally require intact renal clearance.

Frequently Asked Questions

Can I take Allopurinol and Febuxostat together?

No. Both drugs inhibit xanthine oxidase, so combining them offers no added benefit and raises the risk of liver toxicity.

What is the fastest way to lower uric acid?

Starting a low dose of colchicine or a short course of NSAIDs while initiating a urate‑lowering drug provides rapid symptom control. The drug itself takes 2‑4weeks to reach steady‑state urate reduction.

Is Probenecid safe for people with kidney stones?

Probenecid can increase urine uric acid concentration, potentially triggering stone formation. It should be avoided in patients with a history of uric acid stones unless adequate hydration is ensured.

How often should serum urate be checked after switching medication?

Check at 2‑4weeks, then every 3‑6months once the target is stable.

Are there any dietary changes that complement medication?

Limit high‑purine foods (red meat, seafood), avoid excessive alcohol, stay hydrated, and consider a low‑fructose diet to reduce urate production.

Bottom Line

The choice between Allopurinol and its alternatives hinges on kidney function, cardiovascular health, cost, and personal tolerance. Allopurinol stays the go‑to drug for most, but febuxostat shines when renal dose‑adjustments become cumbersome, and probenecid offers a useful uricosuric route for select patients. Lesinurad and topiroxostat expand the toolbox but require careful monitoring. By matching drug properties to patient specifics, clinicians can achieve sustained urate control with minimal side effects.